Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation

2009 ◽  
Vol 16 (1) ◽  
pp. 109-109 ◽  
Author(s):  
Ana Paula Barreiros ◽  
Christian Geber ◽  
Frank Birklein ◽  
Peter R. Galle ◽  
Gerd Otto
2010 ◽  
Vol 52 ◽  
pp. S185-S186
Author(s):  
C. Baliellas ◽  
L. Lladó ◽  
C. Casasnovas ◽  
J. Castellote ◽  
J. Fabregat ◽  
...  

2010 ◽  
Vol 16 (12) ◽  
pp. 1386-1392 ◽  
Author(s):  
Laura Lladó ◽  
Carme Baliellas ◽  
Carlos Casasnovas ◽  
Isidre Ferrer ◽  
Joan Fabregat ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-3 ◽  
Author(s):  
Marina Moguilevitch ◽  
Ellise Delphin

Domino liver transplant has emerged as a viable strategy to increase the number of grafts available for transplantation. In the domino transplant organs explanted from one patient are transplanted into another patient. The first successful domino liver transplant was performed in Portugal in 1995. Since then this innovative concept has been applied to several genetic or biochemical disorders that are treated by liver transplantation. An important consideration during this operation is that such livers can pose a risk of the de novo development of the disease in the recipient. That is why this surgical procedure requires careful planning, proper selection of the patients, and informed consent of both donor and recipient.


2016 ◽  
Vol 22 (5) ◽  
pp. 656-664 ◽  
Author(s):  
Yohei Misumi ◽  
Yasuko Narita ◽  
Toshinori Oshima ◽  
Mitsuharu Ueda ◽  
Taro Yamashita ◽  
...  

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
R Costa ◽  
P Rodrigues ◽  
R Felix ◽  
M Oliveira ◽  
A Frias ◽  
...  

Abstract Introduction Sequential liver transplantation (SLT) uses livers excised from patients with hereditary transthyretin-related amyloidosis during liver transplantation as grafts to other patients with severe hepatic pathologies and a reserved prognosis. We intended to investigate the development of cardiac manifestations consistent with iatrogenic transthyretin amyloidosis (iATTR). Methods We retrospectively analyzed the medical records of 72 consecutive patients submitted to SLT between 2007 and 2010, who received livers with V30M mutation. Results Our sample had 79% male patients and a mean age at transplantation of 55±6 years. Median follow-up time was 80 months, were 44% of the patients died. One-year mortality rate after SLT was 7%. Clinical manifestations of iATTR occurred in 29% of individuals, on average 6 years after SLT, and amyloid was seen in 76% of those who underwent a biopsy. Left ventricular hypertrophy (LVH) was identified in 42 (58%) patients at baseline. Considering 39 patients that had an echocardiography at baseline and during follow-up, 22 (61%) presented de novo LVH or basal LVH worsening during follow-up, with a significant increase of wall thickness (11±1 to 13±3 mm; p<0.001). They had similar age at presentation (55±5 vs 58±5, p=0.249) and incidence of hypertension (52% vs 64%, p=0.365) but higher incidence of chronic kidney disease (CKD; 68% vs 29%, p=0.023). Mortality during follow-up was higher in patients with de novo LVH or worsening LVH but not significantly, probably due to the sample size (23% vs 7%, p=0.221, log rank test p=0.262). Considering the global sample, significant conduction changes were rarely seen (1 patient); however, there was a trend towards an increase in PR interval and atrial fibrillation was reported in 8% of cases. Conclusions In our sample, probable iATTR was often seen within a decade after SLT. Further investigation of LVH needs to be made in these patients, as it can represent amyloid cardiomyopathy, but other contributing factors such as hypertension, CKD and age need to be taken into consideration. In our sample, development of a possible infiltrative pattern was relatively more common and conduction disorders were rarer than one would extrapolate from hereditary early onset ATTR V30M patients. Further studies may help us clarify if indeed these patients behave like late onset ATTR V30M. Our data suggests that these patients should probably undergo periodic cardiac imaging during follow-up. Funding Acknowledgement Type of funding source: None


2020 ◽  
Vol 2 (8) ◽  
pp. 1155-1160
Author(s):  
Yasuhito Hosoda ◽  
Mitsuharu Ueda ◽  
Jun Takaki ◽  
Ken Okamoto ◽  
Taro Yamashita ◽  
...  

2020 ◽  
Vol 21 (1) ◽  
pp. 372-381
Author(s):  
Antonio Grande‐Trillo ◽  
Carmen Baliellas ◽  
Laura Lladó ◽  
Carlos Casasnovas ◽  
Joaquín V. Franco‐Baux ◽  
...  

2010 ◽  
Vol 82 (11) ◽  
pp. 1287-1290 ◽  
Author(s):  
H. Koike ◽  
T. Kiuchi ◽  
M. Iijima ◽  
M. Ueda ◽  
Y. Ando ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document